Add BrightSurf on Google Email

PFAS exposure, high-fat diet drive prostate cells’ metabolism into pro-cancer state

A new study in mice found that PFAS exposure reprograms the metabolism of benign and malignant human prostate cells to a more energy efficient state. Consuming a high-fat diet significantly accelerated development of tumors in PFAS-exposed mice, suggesting a synergistic interaction between the two.

SourceUniversity of Illinois at Urbana-Champaign, News Bureau·JournalNutrients·TypeExperimental study·DateNov 11, 2021

ASTRO: International meta-analysis quantifies impact of three prostate cancer therapy intensification strategies

A new international meta-analysis of randomized clinical trials found that adding androgen deprivation therapy (ADT) to definitive radiotherapy improves metastasis-free survival by 8% and overall survival by 7%. Prolonging adjuvant ADT for 18-36 months also shows similar benefits.

Total androgen suppression with dose-escalated radiotherapy does not improve overall survival in men with intermediate-risk prostate cancer: Results highlight need for biomarker studies

The NRG-RTOG 0815 trial found that adding androgen suppression to dose-escalated radiotherapy did not improve overall survival, but reduced rates of biochemical failure and distant metastases. Future studies are needed to identify subsets of patients who may benefit from this intervention.

Shortened course of radiation therapy offers similar long-term side effects following prostate removal surgery

A recent clinical trial found that a shortened course of radiation therapy after prostate removal surgery does not increase long-term side effects or lower quality of life compared to conventional treatment. Patients who underwent hypofractionated, post-operative radiation therapy experienced comparable genitourinary and gastrointestin...

Targeting cancer at the nanoscale

Scientists at Osaka University developed a novel system for targeted cancer radiation therapy using gold nanoparticles labeled with astatine-211. The nanoparticles are highly toxic to cancer cells while remaining localized, minimizing damage to healthy tissues.

SourceOsaka University·JournalJournal of Nanobiotechnology·TypeExperimental study·DateOct 19, 2021

Targeted prostate cancer screening could benefit men with inherited cancer syndrome

Research suggests that regular PSA testing from age 40 could detect life-threatening prostate cancer in men with genetic hallmarks of Lynch syndrome, increasing the chances of earlier diagnosis and treatment. Men with MSH2 gene faults were eight times more likely to be diagnosed with prostate cancer at a younger age.

SourceInstitute of Cancer Research·JournalThe Lancet Oncology·TypeExperimental study·DateOct 19, 2021

‘Gut bugs’ can drive prostate cancer growth and treatment resistance

A new study found that common gut bacteria can drive prostate cancer growth and treatment resistance by providing an alternative source of growth-promoting androgens. Researchers identified specific bacterial 'fingerprints' linked to prostate cancer outcome, which could help identify men who could benefit from strategies to manipulate ...

SourceInstitute of Cancer Research·JournalScience·TypeExperimental study·DateOct 7, 2021

Cancer breakthrough: Exercise may stop disease in its tracks

A clinical trial found that obese prostate cancer patients who underwent regular exercise training for 12 weeks had increased levels of anti-cancer myokines, which suppressed tumour growth and helped fight cancerous cells. The study suggests exercise may be a key weapon in cancer patients' battle against the disease.

SourceEdith Cowan University·JournalMedicine & Science in Sports & Exercise·TypeRandomized controlled/clinical trial·DateOct 4, 2021

Novartis unveils new data at ESMO 2021, including compelling longest ever reported median overall survival data in advanced breast cancer, as it continues to push the boundaries of innovation

Novartis presents Phase III MONALEESA-2 study results demonstrating improved overall survival with Kisqali (ribociclib) in combination with letrozole. The analysis shows a statistically significant and clinically meaningful improvement in survival, with median OS of 63.9 months.

Studies biased toward white genomes still predict cancer risk in diverse groups

A new study found that genome-wide association studies (GWAS) results from people with European ancestry can still be applied to predict breast and prostate cancer risk in diverse groups. However, the findings emphasize the need for more diverse participants in GWAS analyses to realize the full potential of polygenic risk scores.

SourcePLOS·JournalPLOS Genetics·TypeExperimental study·DateSep 16, 2021

Active surveillance for low-risk prostate cancer: New data on risk factors for switching to active treatment

A study analyzing 6,775 patients with low-risk prostate cancer found that cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment. The study also found that higher Gleason grade, PSA level, tumor stage, and number of positive biopsy cores are related to shorter conversion times.

SourceWolters Kluwer Health·JournalThe Journal of Urology·DateSep 10, 2021

One-half of patients with low-risk prostate cancer switch from active surveillance to active treatment

A population-based study found that nearly half of men with low-risk prostate cancer transitioned from active surveillance to definitive treatment within five years after diagnosis. The study, published in The Journal of Urology, analyzed data from 8,541 men and identified factors associated with the likelihood of transition, including...

SourceWolters Kluwer Health·JournalThe Journal of Urology·DateAug 20, 2021

Patients helping researchers to advance treatments for prostate cancer

Monash University researchers have established a vast collection of living prostate cancer tumors from patients, enabling the testing of new treatments and advancing patient care. The PDX collection comprises 59 tumors collected from 30 patients between 2012-2020, providing a unique resource for scientists and pharmaceutical companies.

SourceMonash University·JournalNature Communications·TypeExperimental study·DateAug 19, 2021

Researchers uncover a way to harness the power of immunotherapy for advanced prostate cancer

Researchers have found a way to harness the power of immunotherapy for advanced prostate cancer by targeting a protein called PIKfyve. Blocking PIKfyve with the inhibitor ESK981 has been shown to increase tumor death and recruit immune T cells, offering new hope for patients with this challenging form of cancer.

SourceMichigan Medicine - University of Michigan·JournalNature Cancer·TypeExperimental study·DateAug 2, 2021

Doctors’ complaint about promotion of harmful dairy products triggers an investigation

The American Academy of Family Physicians is investigating an 'educational' session promoting dairy products linked to increased risk of prostate cancer and other diseases disproportionately affecting African Americans. The Physicians Committee for Responsible Medicine filed a complaint, citing standards set by the Accreditation Counci...

Genomic test could help predict aggressive disease in men newly diagnosed with prostate cancer

A new genomic test may help identify patients at high risk of prostate cancer progression. The Decipher Biopsy test showed that men with high scores needed active treatment sooner, and those who underwent surgery had shorter time until PSA levels increased or they were put on anti-androgen therapy.

SourceMichigan Medicine - University of Michigan·JournalProstate Cancer and Prostatic Diseases·DateJul 27, 2021

New AI tech for early detection of prostate cancer

A new AI-powered diagnostic tool can spot asymptomatic prostate cancer in routine CT scans, allowing for earlier diagnosis and improved treatment outcomes. The technology, developed at RMIT University, has been shown to perform better than human radiologists in detecting cancerous growths.

SourceRMIT University·JournalScientific Reports·DateJul 7, 2021

PSMA-targeted radiotracer pinpoints metastatic prostate cancer across anatomic regions

A phase III clinical trial validates the effectiveness of 18F-DCFPyL in detecting and localizing recurrent prostate cancer, achieving high positive predictive values across various regions. The study's results support the use of PSMA-targeted radiotracers as the most sensitive and accurate agents for imaging prostate cancer.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJun 15, 2021

Decrease in prostate cancer diagnoses due to pandemic

A new study found a 36% decrease in prostate cancer diagnoses in Sweden during the first pandemic wave, with most pronounced declines among men aged 75 and over. The number of patients receiving curative treatment remained unaffected, suggesting that healthcare prioritized cancer care during the pandemic.

SourceUppsala University·JournalScandinavian Journal of Urology·DateApr 29, 2021